The future of breast cancer: the role of prognostic factors View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2005-01

AUTHORS

William J. Gradishar

ABSTRACT

There remains a number of unmet clinical needs in patients with breast cancer that research and development aims to address. More sensitive and specific indicators of prognosis are required to identify those patients at greatest risk for disease progression. A number of biological markers including the cyclins, circulating epithelial cells, and components of the urokinase plasminogen system have been shown to correlate with patient outcome. Genomic analysis also has the potential to predict patient response to specific agents, thus ensuring patients derive the maximum benefit from the treatment they receive. Patients who require treatment are often exposed to the undesirable toxic effects that are associated with some treatments. Liposomal and nanoparticle formulations of currently available agents have been shown to be at least as effective as their parent compounds but with improved safety and tolerability profiles. Studies into patient quality of life during therapy have highlighted the importance of early administration of an erythropoietic agent to treat chemotherapy-induced anemia. Further research in breast cancer should further optimize the treatment patients receive ensuring that patients not only live longer but also have quality survival. More... »

PAGES

s17-s26

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10549-005-0144-y

DOI

http://dx.doi.org/10.1007/s10549-005-0144-y

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1031867849

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/15770535


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biomarkers, Tumor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Breast Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cyclins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Gene Expression Profiling", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Liposomes", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Nanostructures", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Oligonucleotide Array Sequence Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quality of Life", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Division of Hematology/Oncology, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, 676 North St Clair, Suite 850, Chicago, IL, USA", 
          "id": "http://www.grid.ac/institutes/grid.16753.36", 
          "name": [
            "Division of Hematology/Oncology, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, 676 North St Clair, Suite 850, Chicago, IL, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gradishar", 
        "givenName": "William J.", 
        "id": "sg:person.0627760413.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0627760413.21"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/nm0203-152", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012725684", 
          "https://doi.org/10.1038/nm0203-152"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/415530a", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043001094", 
          "https://doi.org/10.1038/415530a"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/bcr732", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052125213", 
          "https://doi.org/10.1186/bcr732"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf03187139", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025273729", 
          "https://doi.org/10.1007/bf03187139"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2005-01", 
    "datePublishedReg": "2005-01-01", 
    "description": "There remains a number of unmet clinical needs in patients with breast cancer that research and development aims to address. More sensitive and specific indicators of prognosis are required to identify those patients at greatest risk for disease progression. A number of biological markers including the cyclins, circulating epithelial cells, and components of the urokinase plasminogen system have been shown to correlate with patient outcome. Genomic analysis also has the potential to predict patient response to specific agents, thus ensuring patients derive the maximum benefit from the treatment they receive. Patients who require treatment are often exposed to the undesirable toxic effects that are associated with some treatments. Liposomal and nanoparticle formulations of currently available agents have been shown to be at least as effective as their parent compounds but with improved safety and tolerability profiles. Studies into patient quality of life during therapy have highlighted the importance of early administration of an erythropoietic agent to treat chemotherapy-induced anemia. Further research in breast cancer should further optimize the treatment patients receive ensuring that patients not only live longer but also have quality survival.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s10549-005-0144-y", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1092777", 
        "issn": [
          "0167-6806", 
          "1573-7217"
        ], 
        "name": "Breast Cancer Research and Treatment", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "Suppl 1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "89"
      }
    ], 
    "keywords": [
      "breast cancer", 
      "chemotherapy-induced anemia", 
      "unmet clinical need", 
      "undesirable toxic effects", 
      "tolerability profile", 
      "early administration", 
      "prognostic factors", 
      "patients' quality", 
      "erythropoietic agents", 
      "treatment patients", 
      "quality survival", 
      "disease progression", 
      "patient outcomes", 
      "patient response", 
      "available agents", 
      "patients", 
      "greater risk", 
      "biological markers", 
      "clinical need", 
      "specific agents", 
      "epithelial cells", 
      "cancer", 
      "plasminogen system", 
      "toxic effects", 
      "treatment", 
      "nanoparticle formulation", 
      "further research", 
      "agents", 
      "improved safety", 
      "specific indicators", 
      "parent compound", 
      "prognosis", 
      "anemia", 
      "therapy", 
      "administration", 
      "progression", 
      "survival", 
      "outcomes", 
      "risk", 
      "markers", 
      "maximum benefit", 
      "safety", 
      "cells", 
      "genomic analysis", 
      "cyclin", 
      "response", 
      "factors", 
      "study", 
      "life", 
      "number", 
      "role", 
      "benefits", 
      "effect", 
      "profile", 
      "need", 
      "indicators", 
      "quality", 
      "development", 
      "research", 
      "potential", 
      "importance", 
      "analysis", 
      "compounds", 
      "components", 
      "future", 
      "formulation", 
      "system"
    ], 
    "name": "The future of breast cancer: the role of prognostic factors", 
    "pagination": "s17-s26", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1031867849"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10549-005-0144-y"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "15770535"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10549-005-0144-y", 
      "https://app.dimensions.ai/details/publication/pub.1031867849"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:33", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_411.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s10549-005-0144-y"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10549-005-0144-y'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10549-005-0144-y'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10549-005-0144-y'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10549-005-0144-y'


 

This table displays all metadata directly associated to this object as RDF triples.

200 TRIPLES      21 PREDICATES      111 URIs      99 LITERALS      21 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10549-005-0144-y schema:about N09030ca2ce13475d91848c72d0ef3adc
2 N0bbbddf940ae4e3fbe71ae265c233ec0
3 N10b739ddbe944622b831096807ef91f3
4 N1911f0f1dc614eb28ecb24892bf7f4bb
5 N550264dfc8994853b43e0f7a964bcbe0
6 N5ed3ee5781544becb764c6a8e13fbf3e
7 N6a82e62019184327a5bf9d55ec790bde
8 N964d1a72fb014f359b5fff6b5d9f7d5a
9 N9a1b7cd975d24c778d55593f6c7f15da
10 Nb0765b9137c94d069509e73c1cf3f74f
11 Nbe5cf458adbc4f9aa19dc1112f040cf4
12 Nd89da767fbcf46b1bd3b6d99d1ca877b
13 Nd8f8dfbb13d941fab72dc1c44916adc9
14 Ne3c43dca0e9246caa792b798f0723467
15 anzsrc-for:11
16 anzsrc-for:1112
17 schema:author N3efd02d31fc54d1993d4241277fb2623
18 schema:citation sg:pub.10.1007/bf03187139
19 sg:pub.10.1038/415530a
20 sg:pub.10.1038/nm0203-152
21 sg:pub.10.1186/bcr732
22 schema:datePublished 2005-01
23 schema:datePublishedReg 2005-01-01
24 schema:description There remains a number of unmet clinical needs in patients with breast cancer that research and development aims to address. More sensitive and specific indicators of prognosis are required to identify those patients at greatest risk for disease progression. A number of biological markers including the cyclins, circulating epithelial cells, and components of the urokinase plasminogen system have been shown to correlate with patient outcome. Genomic analysis also has the potential to predict patient response to specific agents, thus ensuring patients derive the maximum benefit from the treatment they receive. Patients who require treatment are often exposed to the undesirable toxic effects that are associated with some treatments. Liposomal and nanoparticle formulations of currently available agents have been shown to be at least as effective as their parent compounds but with improved safety and tolerability profiles. Studies into patient quality of life during therapy have highlighted the importance of early administration of an erythropoietic agent to treat chemotherapy-induced anemia. Further research in breast cancer should further optimize the treatment patients receive ensuring that patients not only live longer but also have quality survival.
25 schema:genre article
26 schema:isAccessibleForFree false
27 schema:isPartOf N7e7d164a547a4a0cbbf3caf74eaa5835
28 Nc0469cb55ec1473ba09af79ab2e2a714
29 sg:journal.1092777
30 schema:keywords administration
31 agents
32 analysis
33 anemia
34 available agents
35 benefits
36 biological markers
37 breast cancer
38 cancer
39 cells
40 chemotherapy-induced anemia
41 clinical need
42 components
43 compounds
44 cyclin
45 development
46 disease progression
47 early administration
48 effect
49 epithelial cells
50 erythropoietic agents
51 factors
52 formulation
53 further research
54 future
55 genomic analysis
56 greater risk
57 importance
58 improved safety
59 indicators
60 life
61 markers
62 maximum benefit
63 nanoparticle formulation
64 need
65 number
66 outcomes
67 parent compound
68 patient outcomes
69 patient response
70 patients
71 patients' quality
72 plasminogen system
73 potential
74 profile
75 prognosis
76 prognostic factors
77 progression
78 quality
79 quality survival
80 research
81 response
82 risk
83 role
84 safety
85 specific agents
86 specific indicators
87 study
88 survival
89 system
90 therapy
91 tolerability profile
92 toxic effects
93 treatment
94 treatment patients
95 undesirable toxic effects
96 unmet clinical need
97 schema:name The future of breast cancer: the role of prognostic factors
98 schema:pagination s17-s26
99 schema:productId N4e59b860547a47db8b27d0dd3e0eb67e
100 N71e9e35afa144962b1c6fba7608124da
101 Ne273a9c9f8a744b3814380eeb6f551fa
102 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031867849
103 https://doi.org/10.1007/s10549-005-0144-y
104 schema:sdDatePublished 2022-10-01T06:33
105 schema:sdLicense https://scigraph.springernature.com/explorer/license/
106 schema:sdPublisher N306ffe9575f743c7b1ca246f30ae6f2a
107 schema:url https://doi.org/10.1007/s10549-005-0144-y
108 sgo:license sg:explorer/license/
109 sgo:sdDataset articles
110 rdf:type schema:ScholarlyArticle
111 N09030ca2ce13475d91848c72d0ef3adc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Nanostructures
113 rdf:type schema:DefinedTerm
114 N0bbbddf940ae4e3fbe71ae265c233ec0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Female
116 rdf:type schema:DefinedTerm
117 N10b739ddbe944622b831096807ef91f3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Cyclins
119 rdf:type schema:DefinedTerm
120 N1911f0f1dc614eb28ecb24892bf7f4bb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Breast Neoplasms
122 rdf:type schema:DefinedTerm
123 N306ffe9575f743c7b1ca246f30ae6f2a schema:name Springer Nature - SN SciGraph project
124 rdf:type schema:Organization
125 N3efd02d31fc54d1993d4241277fb2623 rdf:first sg:person.0627760413.21
126 rdf:rest rdf:nil
127 N4e59b860547a47db8b27d0dd3e0eb67e schema:name doi
128 schema:value 10.1007/s10549-005-0144-y
129 rdf:type schema:PropertyValue
130 N550264dfc8994853b43e0f7a964bcbe0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Gene Expression Profiling
132 rdf:type schema:DefinedTerm
133 N5ed3ee5781544becb764c6a8e13fbf3e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Liposomes
135 rdf:type schema:DefinedTerm
136 N6a82e62019184327a5bf9d55ec790bde schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Survival Analysis
138 rdf:type schema:DefinedTerm
139 N71e9e35afa144962b1c6fba7608124da schema:name dimensions_id
140 schema:value pub.1031867849
141 rdf:type schema:PropertyValue
142 N7e7d164a547a4a0cbbf3caf74eaa5835 schema:issueNumber Suppl 1
143 rdf:type schema:PublicationIssue
144 N964d1a72fb014f359b5fff6b5d9f7d5a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Prognosis
146 rdf:type schema:DefinedTerm
147 N9a1b7cd975d24c778d55593f6c7f15da schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Treatment Outcome
149 rdf:type schema:DefinedTerm
150 Nb0765b9137c94d069509e73c1cf3f74f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Biomarkers, Tumor
152 rdf:type schema:DefinedTerm
153 Nbe5cf458adbc4f9aa19dc1112f040cf4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Quality of Life
155 rdf:type schema:DefinedTerm
156 Nc0469cb55ec1473ba09af79ab2e2a714 schema:volumeNumber 89
157 rdf:type schema:PublicationVolume
158 Nd89da767fbcf46b1bd3b6d99d1ca877b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Oligonucleotide Array Sequence Analysis
160 rdf:type schema:DefinedTerm
161 Nd8f8dfbb13d941fab72dc1c44916adc9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Antineoplastic Combined Chemotherapy Protocols
163 rdf:type schema:DefinedTerm
164 Ne273a9c9f8a744b3814380eeb6f551fa schema:name pubmed_id
165 schema:value 15770535
166 rdf:type schema:PropertyValue
167 Ne3c43dca0e9246caa792b798f0723467 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Humans
169 rdf:type schema:DefinedTerm
170 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
171 schema:name Medical and Health Sciences
172 rdf:type schema:DefinedTerm
173 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
174 schema:name Oncology and Carcinogenesis
175 rdf:type schema:DefinedTerm
176 sg:journal.1092777 schema:issn 0167-6806
177 1573-7217
178 schema:name Breast Cancer Research and Treatment
179 schema:publisher Springer Nature
180 rdf:type schema:Periodical
181 sg:person.0627760413.21 schema:affiliation grid-institutes:grid.16753.36
182 schema:familyName Gradishar
183 schema:givenName William J.
184 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0627760413.21
185 rdf:type schema:Person
186 sg:pub.10.1007/bf03187139 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025273729
187 https://doi.org/10.1007/bf03187139
188 rdf:type schema:CreativeWork
189 sg:pub.10.1038/415530a schema:sameAs https://app.dimensions.ai/details/publication/pub.1043001094
190 https://doi.org/10.1038/415530a
191 rdf:type schema:CreativeWork
192 sg:pub.10.1038/nm0203-152 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012725684
193 https://doi.org/10.1038/nm0203-152
194 rdf:type schema:CreativeWork
195 sg:pub.10.1186/bcr732 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052125213
196 https://doi.org/10.1186/bcr732
197 rdf:type schema:CreativeWork
198 grid-institutes:grid.16753.36 schema:alternateName Division of Hematology/Oncology, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, 676 North St Clair, Suite 850, Chicago, IL, USA
199 schema:name Division of Hematology/Oncology, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, 676 North St Clair, Suite 850, Chicago, IL, USA
200 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...